New Fluorescence Lifetime Platform Unveiled at SLAS
Product News Jan 22, 2016
Combining their well-established expertise in drug discovery automation plus peptide and protein engineering and manufacture, TTP Labtech and Almac Group have formed a strategic partnership to bring a fully integrated fluorescence lifetime platform. Being launched on Booth 621 at the Society for Laboratory Automation and Screening (SLAS) Conference in San Diego, USA the new platform comprises TTP Labtech’s new ameon® lifetime reader and Almac’s FLEXYTE® lifetime assays and reagents for precise lifetime assays, to provide a simple one-stop shop for robust, cost-effective drug screening and profiling.
On the booth, the new compact ameon lifetime reader will be on show which offers a step-change in lifetime data acquisition. Experts will also be on hand to explain how the reader can be combined with FLEXYTE lifetime reagents for the screening of common drug targets such as protein kinases and proteases, as well as challenging epigenetic targets. Applying such a powerful combination allows researchers to reduce compound-related assay interference, select fewer false leads and obtain the reliability normally associated with biophysical methods at the compound screen stage.
For scientists wanting to find out more about the unrivalled advantages of this accessible lifetime technology, there is a lunch tutorial entitled “An exciting talk: use of fluorescence lifetime technologies for high-throughput protein kinase screening and profiling” delivered by leading industry speakers on Monday 25th January from 12.30-13.15 in Room 1A. Please click the link to register http://discover.ttplabtech.com/SLAS-2016-lifetime-workshop.html There are poster presentations from AstraZeneca and GlaxoSmithKline detailing their recent experience with the platform and further information is also available by clicking the link: http://ttplabtech.com/biochemical-screening-2/ameon_lifetime_reader/
Dr Wayne Bowen, CSO at TTP Labtech, stated: “We have listened, and in partnership with major pharma companies, have developed an intelligent approach to improve the efficiency of compound screening. Most screening methodologies continue to be impacted by too many false hits and the limited throughput of orthogonal biophysical technologies; the intrinsic robustness of Almac’s FLEXYTE lifetime reagents coupled with the precision of TTP Labtech’s new ameon lifetime reader sets a new benchmark for cost-effective screening through better discrimination of lead compounds at an earlier stage within the drug discovery process.”
Dr Charles Shields, VP of Peptides & Small Molecule API at Almac commented: "We believe that the strategic partnership between TTP Labtech and Almac will bring to the screening community a true step-change in assay performance with the ability to uncover previously obscured leads and the potential to access new chemical space."